<DOC>
	<DOCNO>NCT01591655</DOCNO>
	<brief_summary>The objective clinical study compare safety efficacy mapracorat ophthalmic suspension , 3 % vehicle treatment postoperative inflammation pain follow cataract surgery . Participants United States Canada recruit study .</brief_summary>
	<brief_title>Mapracorat Ophthalmic Suspension , 3 % Treatment Ocular Inflammation Pain Following Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<criteria>Subjects candidate routine , uncomplicated cataract surgery . Subjects , Investigator 's opinion , potential postoperative pinhole Snellen visual acuity ( VA ) least 20/200 study eye . Subjects â‰¥ Grade 2 ( 6 15 cell ) AC cell study eye follow cataract surgery ( postoperative day 1 ) . Subjects severe/serious ocular condition history/presence chronic generalize systemic disease Investigator feel might increase risk subject confound result ( ) study . Any intraocular inflammation either eye ( cell flare score great Grade 0 slit lamp examination ) ocular pain great Grade 1 study eye Screening Visit . Presence active external ocular disease : infection inflammation study eye . Subjects know hypersensitivity contraindication study drug ( ) component . Subjects currently require expect require treatment medication list disallowed medication per Disallowed Therapy section protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>